{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:13:27Z","timestamp":1778793207104,"version":"3.51.4"},"reference-count":28,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,8,30]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study evaluated the efficacy and safety of avacopan versus a prednisone taper in the subgroup of patients with antineutrophil cytoplasmic antibody-associated vasculitis (granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)) receiving cyclophosphamide (CYC) followed by azathioprine (or mycophenolate mofetil) in the ADVOCATE trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Key efficacy outcomes were remission at week 26 and sustained remission at week 52. Additional outcomes included glucocorticoid toxicity, estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR) and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 330 patients receiving study medication, 116 (35.2%) received CYC (avacopan group, n=59; prednisone taper group, n=57). Remission at week 26 and sustained remission at week 52 were achieved by 37\/59 (62.7%) and 33\/59 (55.9%) patients in the avacopan group and 34\/57 (59.6%) and 30\/57 (52.6%) in the prednisone taper group, respectively. Over 52 weeks, relapses were observed in 13.0% in the avacopan group and 22.6% in the prednisone taper group. Improvement in eGFR, speed of albuminuria reduction and differences in glucocorticoid toxicity favoured the avacopan group. Serious adverse events occurred in 55.9% and 56.1% of patients in the avacopan and prednisone taper groups, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This subgroup analysis of patients who received CYC shows similar rates of remission in the avacopan and prednisone taper groups. Compared with the prednisone taper regimen, the avacopan regimen was associated with a numerically lower relapse rate, greater improvement in eGFR, faster reduction in UACR, lower glucocorticoid-related toxicity and similar overall safety. These results support the use of avacopan in combination with CYC to treat GPA or MPA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02994927\">NCT02994927<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-005743","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:35:19Z","timestamp":1759732519000},"page":"e005743","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02994927","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02994927","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Duvuru","family":"Geetha","sequence":"first","affiliation":[{"name":"Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Neumann","sequence":"additional","affiliation":[{"name":"Kantonsspital St Gallen, St. Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Karras","sequence":"additional","affiliation":[{"name":"Universite Paris Descartes, Paris, France"},{"name":"Hopital Europeen Georges Pompidou, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Cid","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Bray","sequence":"additional","affiliation":[{"name":"Amgen Ltd, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5516-315X","authenticated-orcid":false,"given":"Alana M.","family":"Bozeman","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0637","authenticated-orcid":false,"given":"David R. W.","family":"Jayne","sequence":"additional","affiliation":[{"name":"University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,5]]},"reference":[{"key":"2026010700550741000_11.4.e005743.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197908023010503"},{"key":"2026010700550741000_11.4.e005743.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.008"},{"key":"2026010700550741000_11.4.e005743.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764"},{"key":"2026010700550741000_11.4.e005743.4","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026010700550741000_11.4.e005743.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200721"},{"key":"2026010700550741000_11.4.e005743.6","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1093\/rheumatology\/kead087","article-title":"CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum","volume":"62","author":"Turgeon","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026010700550741000_11.4.e005743.7","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014010046"},{"key":"2026010700550741000_11.4.e005743.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169"},{"key":"2026010700550741000_11.4.e005743.9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4078\/jrd.2022.0002","article-title":"Management of antineutrophil cytoplasmic antibody-associated vasculitis: a review of recent guidelines","volume":"30","author":"Ahn","year":"2023","journal-title":"J Rheum Dis"},{"key":"2026010700550741000_11.4.e005743.10","doi-asserted-by":"crossref","first-page":"i60","DOI":"10.1093\/ndt\/gfu392","article-title":"The long-term outcomes of systemic vasculitis","volume":"30 Suppl 1","author":"Westman","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2026010700550741000_11.4.e005743.11","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.40776","article-title":"Effect of disease activity at three and six months after diagnosis on long-term outcomes in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"Gopaluni","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026010700550741000_11.4.e005743.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137778"},{"key":"2026010700550741000_11.4.e005743.13","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/art.39614","article-title":"Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease","volume":"68","author":"Rhee","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026010700550741000_11.4.e005743.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023386"},{"key":"2026010700550741000_11.4.e005743.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224816"},{"key":"2026010700550741000_11.4.e005743.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101279"},{"key":"2026010700550741000_11.4.e005743.17","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5"},{"key":"2026010700550741000_11.4.e005743.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715"},{"key":"2026010700550741000_11.4.e005743.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152010"},{"key":"2026010700550741000_11.4.e005743.20","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00004"},{"key":"2026010700550741000_11.4.e005743.21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/hr.2010.244","article-title":"Prognostic significance of glomerular filtration rate estimated by the Japanese equation among patients who underwent complete coronary revascularization","volume":"34","author":"Kasai","year":"2011","journal-title":"Hypertens Res"},{"key":"2026010700550741000_11.4.e005743.22","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008030287"},{"key":"2026010700550741000_11.4.e005743.23","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 Health Survey Update","volume":"25","author":"Ware","year":"2000","journal-title":"Spine (Phila Pa 1986)"},{"key":"2026010700550741000_11.4.e005743.24","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2026010700550741000_11.4.e005743.25","unstructured":"International Conference on Harmonisation (ICH) . Introductory guide meddra version 19.1. 2016. Available: https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_19_1_english.pdf [accessed 20 Jan 2025]"},{"key":"2026010700550741000_11.4.e005743.26","unstructured":"U.S Department of Health and Human Services . Common terminology criteria for adverse events (CTCAE) version 5.0. 2017. Available: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf#search=%22CTCAE%22.pdf [Accessed 20 Jan 2025]."},{"key":"2026010700550741000_11.4.e005743.27","unstructured":"TAVNEOS (avacopan) . Prescribing information. Thousand Oaks, CA, USA Amgen. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214487s000lbl.pdf [accessed 14 Mar 2025]"},{"key":"2026010700550741000_11.4.e005743.28","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014090903"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:55:14Z","timestamp":1767776114000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,5]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/rmdopen-2025-005743"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005743","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}